Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Michael Bristow
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Anatomy
Procedures
Physiology
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
44
Renlund, Dale
42
Gilbert, Edward
33
Lowes, Brian
24
Minobe, Wayne
23
Feldman, Arthur
23
Abraham, William
20
Robertson, Alastair
20
Port, J. David
19
Hershberger, Ray
18
Hammond, Elizabeth
16
Lindenfeld, JoAnn
12
Roden, Robert
12
Wolfel, Eugene
11
Zisman, Lawrence
10
Taylor, DO
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Michael Bristow (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Movsesian Matthew; Stehlik Josef; Vandeput Fabrice; Bristow Michael R
Phosphodiesterase inhibition in heart failure.
Heart failure reviews 2009;14(4):255-63.
-
2009: Saxon Leslie A; Olshansky Brian; Volosin Kent; Steinberg Jonathan S; Lee Byron K; Tomassoni Gery; Guarnieri Thomas; Rao Anupama; Yong Patrick; Galle Elizabeth; Leigh Jill; Ecklund Fred; Bristow Michael R
Influence of left ventricular lead location on outcomes in the COMPANION study.
Journal of cardiovascular electrophysiology 2009;20(7):764-8.
-
2009: MacGregor John F; Blake Wachter S; Munger Mark; Stoddard Greg; Bristow Michael R; Gilbert Edward M
Carvedilol produces sustained long-term benefits: follow-up at 12 years.
Congestive heart failure (Greenwich, Conn.) 2009;15(1):5-8.
-
2009: Taylor Matthew R G; Slavov Dobromir; Humphrey Kurt; Zhao Lan; Cockroft Jennifer; Zhu Xiao; Lavori Philip; Bristow Michael R; Mestroni Luisa; Lazzeroni Laura C
Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.
Pharmacogenetics and genomics 2009;19(1):35-43.
-
2008: Sucharov Carmen; Bristow Michael R; Port J David
miRNA expression in the failing human heart: functional correlates.
Journal of molecular and cellular cardiology 2008;45(2):185-92.
-
2008: De Marco Teresa; Wolfel Eugene; Feldman Arthur M; Lowes Brian; Higginbotham Michael B; Ghali Jalal K; Wagoner Lynne; Kirlin Philip C; Kennett Jerry D; Goel Satish; Saxon Leslie A; Boehmer John P; Mann David; Galle Elizabeth; Ecklund Fred; Yong Patrick; Bristow Michael R
Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study.
Journal of cardiac failure 2008;14(1):9-18.
-
2008: Sauer William H; Bristow Michael R
The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective.
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2008;21(1):3-11.
-
2007: Lowes Brian D; Zolty Ronald; Shakar Simon F; Brieke Andreas; Gray Norman; Reed Michael; Calalb Mihail; Minobe Wayne; Lindenfeld JoAnn; Wolfel Eugene E; Geraci Mark; Bristow Michael R; Cleveland Joseph
Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2007;26(11):1170-6.
-
2007: Ghali Jalal K; Boehmer John; Feldman Arthur M; Saxon Leslie A; Demarco Teresa; Carson Peter; Yong Patrick; Galle Elizabeth G; Leigh Jill; Ecklund Fred L; Bristow Michael R
Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
Journal of cardiac failure 2007;13(9):769-73.
-
2007: Tate Charles W; Robertson Alastair D; Zolty Ronald; Shakar Simon F; Lindenfeld Joann; Wolfel Eugene E; Bristow Michael R; Lowes Brian D
Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST).
Journal of cardiac failure 2007;13(9):732-7.
-
2007: Feldman Arthur M; Oren Ron M; Abraham William T; Boehmer John P; Carson Peter E; Eichhorn Eric; Gilbert Edward M; Kao Andrew; Leier Carl V; Lowes Brian D; Mathier Michael A; McGrew Frank A; Metra Marco; Zisman Lawrence S; Shakar Simon F; Krueger Steven K; Robertson Alastair D; White Bill G; Gerber Michael J; Wold Gwyn E; Bristow Michael R;
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
American heart journal 2007;154(5):861-9.
-
2007: Sparagna Genevieve C; Chicco Adam J; Murphy Robert C; Bristow Michael R; Johnson Christopher A; Rees Meredith L; Maxey Melissa L; McCune Sylvia A; Moore Russell L
Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure.
Journal of lipid research 2007;48(7):1559-70.
-
2007: Taylor Matthew R G; Slavov Dobromir; Ku Lisa; Di Lenarda Andrea; Sinagra Gianfranco; Carniel Elisa; Haubold Kurt; Boucek Mark M; Ferguson Debra; Graw Sharon L; Zhu Xiao; Cavanaugh Jean; Sucharov Carmen C; Long Carlin S; Bristow Michael R; Lavori Philip; Mestroni Luisa;
Prevalence of desmin mutations in dilated cardiomyopathy.
Circulation 2007;115(10):1244-51.
-
2007: Lindenfeld JoAnn; Feldman Arthur M; Saxon Leslie; Boehmer John; Carson Peter; Ghali Jalal K; Anand Inder; Singh Steve; Steinberg Jonathan S; Jaski Brian; DeMarco Teresa; Mann David; Yong Patrick; Galle Elizabeth; Ecklund Fred; Bristow Michael
Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
Circulation 2007;115(2):204-12.
-
2007: Taylor Matthew R G; Ku Lisa; Slavov Dobromir; Cavanaugh Jean; Boucek Mark; Zhu Xiao; Graw Sharon; Carniel Elisa; Barnes Carl; Quan Dianna; Prall Ryan; Lovell Mark A; Mierau Gary; Ruegg Patsy; Mandava Naresh; Bristow Michael R; Towbin Jeffrey A; Mestroni Luisa;
Danon disease presenting with dilated cardiomyopathy and a complex phenotype.
Journal of human genetics 2007;52(10):830-5.
-
2006: Saxon Leslie A; Bristow Michael R; Boehmer John; Krueger Steven; Kass David A; De Marco Teresa; Carson Peter; DiCarlo Lorenzo; Feldman Arthur M; Galle Elizabeth; Ecklund Fred
Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial.
Circulation 2006;114(25):2766-72.
-
2006: Bush Erik W; Hood David B; Papst Philip J; Chapo Joseph A; Minobe Wayne; Bristow Michael R; Olson Eric N; McKinsey Timothy A
Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling.
The Journal of biological chemistry 2006;281(44):33487-96.
-
2006: Sucharov Carmen C; Langer Stephen; Bristow Michael; Leinwand Leslie
Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CaMKIV/PKD and PP2A.
American journal of physiology. Cell physiology 2006;291(5):C1029-37.
-
2006: Sucharov Carmen C; Mariner Peter D; Nunley Karin R; Long Carlin; Leinwand Leslie; Bristow Michael R
A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction.
American journal of physiology. Heart and circulatory physiology 2006;291(3):H1299-308.
-
2006: Liggett Stephen B; Mialet-Perez Jeanne; Thaneemit-Chen Surai; Weber Stewart A; Greene Scott M; Hodne Danielle; Nelson Bradley; Morrison Jennifer; Domanski Michael J; Wagoner Lynne E; Abraham William T; Anderson Jeffrey L; Carlquist John F; Krause-Steinrauf Heidi J; Lazzeroni Laura C; Port J David; Lavori Philip W; Bristow Michael R
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(30):11288-93.
-
2006: Quaife Robert A; Chen Marcus Y; Lynch David; Badesch David B; Groves Bertron M; Wolfel Eugene; Robertson Alastair D; Bristow Michael R; Voelkel Norbert F
Importance of right ventricular end-systolic regional wall stress in idiopathic pulmonary arterial hypertension: a new method for estimation of right ventricular wall stress.
European journal of medical research 2006;11(5):214-20.
-
2006: Lowes Brian D; Zolty Ronald; Minobe Wayne A; Robertson Alastair D; Leach Sonia; Hunter Lawrence; Bristow Michael R
Serial gene expression profiling in the intact human heart.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2006;25(5):579-88.
-
2006: Xu Ya; Lu Li; Greyson Clifford; Rizeq Mona; Nunley Karin; Wyatt Beata; Bristow Michael R; Long Carlin S; Schwartz Gregory G
The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs.
American journal of physiology. Heart and circulatory physiology 2006;290(5):H1798-807.
-
2006: Taylor Matthew R; Bristow Michael R
Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure.
Novartis Foundation symposium 2006;274():73-83; discussion 83-9, 152-5, 272-6.
-
2005: Lowes Brian D; Shakar Simon F; Metra Marco; Feldman Arthur M; Eichhorn Eric; Freytag J William; Gerber Michael J; Liard Jean-Francois; Hartman Craig; Gorczynski Rick; Evans Gwyn; Linseman Jennifer V; Stewart Jennifer; Robertson Alastair D; Roecker Ellen B; Demets David L; Bristow Michael R
Rationale and design of the enoximone clinical trials program.
Journal of cardiac failure 2005;11(9):659-69.
-
2005: Carson Peter; Anand Inder; O'Connor Christopher; Jaski Brian; Steinberg Jonathan; Lwin Amy; Lindenfeld JoAnn; Ghali Jalal; Barnet Jodi H; Feldman Arthur M; Bristow Michael R
Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial.
Journal of the American College of Cardiology 2005;46(12):2329-34.
-
2005: Feldman Arthur M; de Lissovoy Gregory; Bristow Michael R; Saxon Leslie A; De Marco Teresa; Kass David A; Boehmer John; Singh Steven; Whellan David J; Carson Peter; Boscoe Audra; Baker Timothy M; Gunderman Matthew R
Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
Journal of the American College of Cardiology 2005;46(12):2311-21.
-
2005: Taylor Matthew R G; Slavov Dobromir; Gajewski Andreas; Vlcek Sylvia; Ku Lisa; Fain Pamela R; Carniel Elisa; Di Lenarda Andrea; Sinagra Gianfranco; Boucek Mark M; Cavanaugh Jean; Graw Sharon L; Ruegg Patsy; Feiger Jennie; Zhu Xiao; Ferguson Debra A; Bristow Michael R; Gotzmann Josef; Foisner Roland; Mestroni Luisa;
Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy.
Human mutation 2005;26(6):566-74.
-
2005: Rivera Dee Ann; Bristow Michael R
Cardiac resynchronization--a heart failure perspective.
Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2005;10(4 Suppl):16-23.
-
2005: Feldman David S; Carnes Cynthia A; Abraham William T; Bristow Michael R
Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure.
Nature clinical practice. Cardiovascular medicine 2005;2(9):475-83.
-
2005: Carniel Elisa; Taylor Matthew R G; Sinagra Gianfranco; Di Lenarda Andrea; Ku Lisa; Fain Pamela R; Boucek Mark M; Cavanaugh Jean; Miocic Snjezana; Slavov Dobromir; Graw Sharon L; Feiger Jennie; Zhu Xiao Zhong; Dao Dmi; Ferguson Debra A; Bristow Michael R; Mestroni Luisa
Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy.
Circulation 2005;112(1):54-9.
-
2005: Kinugawa Koichiro; Jeong Mark Y; Bristow Michael R; Long Carlin S
Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase.
Molecular endocrinology (Baltimore, Md.) 2005;19(6):1618-28.
-
2005: Domanski M; Fleg J; Bristow M; Knox S
The effect of gender on outcome in digitalis-treated heart failure patients.
Journal of cardiac failure 2005;11(2):83-6.
-
2005: Bristow Michael R; Adams Kirkwood F; Bauman Jerry L; Feldman Arthur M; Giles Thomas D; Goldstein Sidney; Mann Douglas L; Talbert Robert L
The COMET trial.
Congestive heart failure (Greenwich, Conn.) 2005;11(1):39-47.
-
2004: Pittenger Basil; Gill Edward A; Holcslaw Terry L; Bristow Michael R
Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy.
The American journal of cardiology 2004;94(11):1459-62.
-
2004: Sucharov Carmen C; Helmke Steve M; Langer Stephen J; Perryman M Benjamin; Bristow Michael; Leinwand Leslie
The Ku protein complex interacts with YY1, is up-regulated in human heart failure, and represses alpha myosin heavy-chain gene expression.
Molecular and cellular biology 2004;24(19):8705-15.
-
2004: Bristow M R; Krause-Steinrauf H; Nuzzo R; Liang Cheng-Seng; Lindenfeld J; Lowes B D; Hattler B; Abraham W T; Olson L; Krueger S; Thaneemit-Chen S; Hare J M; Loeb H S; Domanski M J; Eichhorn E J; Zelis R; Lavori P
Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
Circulation 2004;110(11):1437-42.
-
2004: Bristow Michael R; Saxon Leslie A; Boehmer John; Krueger Steven; Kass David A; De Marco Teresa; Carson Peter; DiCarlo Lorenzo; DeMets David; White Bill G; DeVries Dale W; Feldman Arthur M;
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
The New England journal of medicine 2004;350(21):2140-50.
-
2004: Helmke Steve M; Yen Chia-Yu; Cios Krzysztof J; Nunley Karin; Bristow Michael R; Duncan Mark W; Perryman M Benjamin
Simultaneous quantification of human cardiac alpha- and beta-myosin heavy chain proteins by MALDI-TOF mass spectrometry.
Analytical chemistry 2004;76(6):1683-9.
-
2004: Shakar Simon F; Lowes Brian D; Lindenfeld Joann; Zolty Ronald; Simon Marc; Robertson Alastair D; Bristow Michael R; Wolfel Eugene E
Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers.
Journal of cardiac failure 2004;10(1):15-20.
-
2003: Bristow Michael R; Feldman Arthur M; Adams Kirkwood F; Goldstein Sidney
Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
Journal of cardiac failure 2003;9(6):444-53.
-
2003: Domanski Michael; Krause-Steinrauf Heidi; Deedwania Prakash; Follmann Dean; Ghali Jalal K; Gilbert Edward; Haffner Steven; Katz Richard; Lindenfeld JoAnn; Lowes Brian D; Martin Wade; McGrew Frank; Bristow Michael R;
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
Journal of the American College of Cardiology 2003;42(5):914-22.
-
2003: Sucharov Carmen C; Mariner Peter; Long Carlin; Bristow Michael; Leinwand Leslie
Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter.
The Journal of biological chemistry 2003;278(33):31233-9.
-
2003: Abraham William T; Raynolds Mary V; Badesch David B; Wynne Kristine M; Groves Bertron M; Roden Robert L; Robertson Alastair D; Lowes Brian D; Zisman Lawrence S; Voelkel Norbert F; Bristow Michael R; Perryman M Benjamin
Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2003;4(1):27-30.
-
2003: Linseman Jennifer V; Bristow Michael R
Drug therapy and heart failure prevention.
Circulation 2003;107(9):1234-6.
-
2003: Taylor Matthew R G; Fain Pamela R; Sinagra Gianfranco; Robinson Misi L; Robertson Alastair D; Carniel Elisa; Di Lenarda Andrea; Bohlmeyer Teresa J; Ferguson Debra A; Brodsky Gary L; Boucek Mark M; Lascor Jean; Moss Andrew C; Li Wai Lun P; Stetler Gary L; Muntoni Francesco; Bristow Michael R; Mestroni Luisa;
Natural history of dilated cardiomyopathy due to lamin A/C gene mutations.
Journal of the American College of Cardiology 2003;41(5):771-80.
-
2003: Bristow Michael
Antiadrenergic therapy of chronic heart failure: surprises and new opportunities.
Circulation 2003;107(8):1100-2.
-
2003: Bohlmeyer Teresa; Ferdensi Anthony; Bristow Michael R; Takahashi Saori; Zisman Lawrence S
Selective activation of N-acyl-D-glucosamine 2-epimerase expression in failing human heart ventricular myocytes.
Journal of cardiac failure 2003;9(1):59-68.
-
2003: Bohlmeyer Teresa J; Helmke Steve; Ge Shuping; Lynch Jennifer; Brodsky Gary; Sederberg James H; Robertson Alastair D; Minobe Wayne; Bristow Michael R; Perryman M Benjamin
Hypoplastic left heart syndrome myocytes are differentiated but possess a unique phenotype.
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2003;12(1):23-31.
-
2002: Abraham W T; Gilbert E M; Lowes B D; Minobe W A; Larrabee P; Roden R L; Dutcher D; Sederberg J; Lindenfeld J A; Wolfel E E; Shakar S F; Ferguson D; Volkman K; Linseman J V; Quaife R A; Robertson A D; Bristow M R
Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype.
Molecular medicine (Cambridge, Mass.) 2002;8(11):750-60.
-
2002: Asano Koji; Bohlmeyer Teresa J; Westcott Jay Y; Zisman Lawrence; Kinugawa Koichiro; Good Matthew; Minobe Wayne A; Roden Robert; Wolfel Eugene E; Lindenfeld Joann; David Port J; Perryman M Benjamin; Clevel Joseph; Lowes Brian D; Bristow Michael R
Altered expression of endothelin receptors in failing human left ventricles.
Journal of molecular and cellular cardiology 2002;34(7):833-46.
-
2002: Lowes Brian D; Gilbert Edward M; Abraham William T; Minobe Wayne A; Larrabee Patti; Ferguson Debra; Wolfel Eugene E; Lindenfeld JoAnn; Tsvetkova Tatiana; Robertson Alastair D; Quaife Robert A; Bristow Michael R
Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents.
The New England journal of medicine 2002;346(18):1357-65.
-
2002: Leier Carl V; Silver Marc A; Rich Michael W; Eichhorn Eric J; Fowler Michael B; Giles Thomas D; Johnstone David E; Le Jemtel Thierry H; Lachmann Justine S; Levine T Barry; Armstrong Paul W; Dec William G; Jessup Mariell; Howlett Jonathan; Hershberger Raymond E; Cohn Jay N; Adams Kirkwood F; Colucci Wilson S; Warner-Stevenson Lynne; Hosenpud Jeffrey D; Bristow Michael R; Pina Ileana; Baughman Kenneth L; Binkley Philip F; Ventura Hector O; Francis Gary S; White Michel; Miller Leslie W; Berry Brandy; Missov Emil
Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment.
Congestive heart failure (Greenwich, Conn.) 2002;8(2):98-124.
-
2001: Lowes B D; Tsvetkova T; Eichhorn E J; Gilbert E M; Bristow M R
Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol.
International journal of cardiology 2001;81(2-3):141-9.
-
2001: Lindenfeld J; Robertson A D; Lowes B D; Bristow M R;
Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
Journal of the American College of Cardiology 2001;38(7):1950-6.
-
2001: Kinugawa K; Long C S; Bristow M R
Expression of TR isoforms in failing human heart.
The Journal of clinical endocrinology and metabolism 2001;86(10):5089-90.
-
2001: Port J D; Bristow M R
beta-Adrenergic receptors, transgenic mice, and pharmacological model systems.
Molecular pharmacology 2001;60(4):629-31.
-
2001: Kinugawa K; Yonekura K; Ribeiro R C; Eto Y; Aoyagi T; Baxter J D; Camacho S A; Bristow M R; Long C S; Simpson P C
Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy.
Circulation research 2001;89(7):591-8.
-
2001: Bristow M R; Shakar S F; Linseman J V; Lowes B D
Inotropes and beta-blockers: is there a need for new guidelines?
Journal of cardiac failure 2001;7(2 Suppl 1):8-12.
-
2001: Loh E; Elkayam U; Cody R; Bristow M; Jaski B; Colucci W S
A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure.
Journal of cardiac failure 2001;7(2):114-21.
-
2001: Asano K; Zisman L S; Yoshikawa T; Headley V; Bristow M R; Port J D
Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes.
Journal of cardiovascular pharmacology 2001;37(6):678-91.
-
2001: Fowler M B; Vera-Llonch M; Oster G; Bristow M R; Cohn J N; Colucci W S; Gilbert E M; Lukas M A; Lacey M J; Richner R; Young S T; Packer M
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
Journal of the American College of Cardiology 2001;37(6):1692-9.
-
2001: Port J D; Bristow M R
Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure.
Journal of molecular and cellular cardiology 2001;33(5):887-905.
-
2001: Yancy C W; Fowler M B; Colucci W S; Gilbert E M; Bristow M R; Cohn J N; Lukas M A; Young S T; Packer M;
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
The New England journal of medicine 2001;344(18):1358-65.
-
2001: Shakar S F; Bristow M R
Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.
Current cardiology reports 2001;3(3):224-31.
-
2001: Schleman K A; Lindenfeld J A; Lowes B D; Bristow M R; Ferguson D; Wolfel E E; Abraham W T; Zisman L S
Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis.
Journal of cardiac failure 2001;7(1):4-12.
-
2001: Kinugawa K; Minobe W A; Wood W M; Ridgway E C; Baxter J D; Ribeiro R C; Tawadrous M F; Lowes B A; Long C S; Bristow M R
Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression.
Circulation 2001;103(8):1089-94.
-
2000: Bristow M
Etomoxir: a new approach to treatment of chronic heart failure.
Lancet 2000;356(9242):1621-2.
-
2000: Bristow M R; Feldman A M; Saxon L A
Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators.
Journal of cardiac failure 2000;6(3):276-85.
-
2000: Lowes B D; Higginbotham M; Petrovich L; DeWood M A; Greenberg M A; Rahko P S; Dec G W; LeJemtel T H; Roden R L; Schleman M M; Robertson A D; Gorczynski R J; Bristow M R
Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group.
Journal of the American College of Cardiology 2000;36(2):501-8.
-
2000: Bristow M R
Mechanistic and clinical rationales for using beta-blockers in heart failure.
Journal of cardiac failure 2000;6(2 Suppl 1):8-14.
-
2000: Noori A; Lindenfeld J; Wolfel E; Ferguson D; Bristow M R; Lowes B D
Beta-blockade in adriamycin-induced cardiomyopathy.
Journal of cardiac failure 2000;6(2):115-9.
-
2000: Bisognano J D; Weinberger H D; Bohlmeyer T J; Pende A; Raynolds M V; Sastravaha A; Roden R; Asano K; Blaxall B C; Wu S C; Communal C; Singh K; Colucci W; Bristow M R; Port D J
Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice.
Journal of molecular and cellular cardiology 2000;32(5):817-30.
-
2000: Lowes B D; Simon M A; Tsvetkova T O; Bristow M R
Inotropes in the beta-blocker era.
Clinical cardiology 2000;23(3 Suppl):III11-6.
-
2000: Miyata S; Minobe W; Bristow M R; Leinwand L A
Myosin heavy chain isoform expression in the failing and nonfailing human heart.
Circulation research 2000;86(4):386-90.
-
2000: Bristow M R
beta-adrenergic receptor blockade in chronic heart failure.
Circulation 2000;101(5):558-69.
-
1999: Lindenfeld J; Lowes B D; Bristow M R
Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol.
The Annals of pharmacotherapy 1999;33(12):1266-9.
-
1999: Lowes B D; Gill E A; Abraham W T; Larrain J R; Robertson A D; Bristow M R; Gilbert E M
Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure.
The American journal of cardiology 1999;83(8):1201-5.
-
1999: Quaife R A; Lynch D; Badesch D B; Voelkel N F; Lowes B D; Robertson A D; Bristow M R
Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy.
Journal of cardiac failure 1999;5(1):46-54.
-
1999: Bristow M R
Mechanisms of development of heart failure in the hypertensive patient.
Cardiology 1999;92 Suppl 1():3-6; discussion 7-9, 20-1.
-
1998: Gerdes A M; Onodera T; Tamura T; Said S; Bohlmeyer T J; Abraham W T; Bristow M R
New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material.
Journal of cardiac failure 1998;4(4):343-8.
-
1998: Bristow M R; Roden R L; Lowes B D; Gilbert E M; Eichhorn E J
The role of third-generation beta-blocking agents in chronic heart failure.
Clinical cardiology 1998;21(12 Suppl 1):I3-13.
-
1998: Zisman L S; Asano K; Dutcher D L; Ferdensi A; Robertson A D; Jenkin M; Bush E W; Bohlmeyer T; Perryman M B; Bristow M R
Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart.
Circulation 1998;98(17):1735-41.
-
1998: Bristow M R
Why does the myocardium fail? Insights from basic science.
Lancet 1998;352 Suppl 1():SI8-14.
-
1998: Bristow M R; Zisman L S; Lowes B D; Abraham W T; Badesch D B; Groves B M; Voelkel N F; Lynch D M; Quaife R A
The pressure-overloaded right ventricle in pulmonary hypertension.
Chest 1998;114(1 Suppl):101S-106S.
-
1998: Shakar S F; Abraham W T; Gilbert E M; Robertson A D; Lowes B D; Zisman L S; Ferguson D A; Bristow M R
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
Journal of the American College of Cardiology 1998;31(6):1336-40.
-
1998: Abraham W T; Lowes B D; Ferguson D A; Odom J; Kim J K; Robertson A D; Bristow M R; Schrier R W
Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.
Journal of cardiac failure 1998;4(1):37-44.
-
1998: Quaife R A; Christian P E; Gilbert E M; Datz F L; Volkman K; Bristow M R
Effects of carvedilol on right ventricular function in chronic heart failure.
The American journal of cardiology 1998;81(2):247-50.
-
1998: Bristow M; Port J D
Beta-adrenergic blockade in chronic heart failure.
Scandinavian cardiovascular journal. Supplement 1998;47():45-55.
-
1997: Bristow M R
Mechanism of action of beta-blocking agents in heart failure.
The American journal of cardiology 1997;80(11A):26L-40L.
-
1997: Nakao K; Minobe W; Roden R; Bristow M R; Leinwand L A
Myosin heavy chain gene expression in human heart failure.
The Journal of clinical investigation 1997;100(9):2362-70.
-
1997: Lowes B D; Minobe W; Abraham W T; Rizeq M N; Bohlmeyer T J; Quaife R A; Roden R L; Dutcher D L; Robertson A D; Voelkel N F; Badesch D B; Groves B M; Gilbert E M; Bristow M R
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.
The Journal of clinical investigation 1997;100(9):2315-24.
-
1997: Cohn J N; Fowler M B; Bristow M R; Colucci W S; Gilbert E M; Kinhal V; Krueger S K; Lejemtel T; Narahara K A; Packer M; Young S T; Holcslaw T L; Lukas M A
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
Journal of cardiac failure 1997;3(3):173-9.
-
1997: Bristow M R; Abraham W T; Yoshikawa T; White M; Hattler B G; Crisman T S; Lowes B D; Robertson A D; Larrabee P; Gilbert E M
Second- and third-generation beta-blocking drugs in chronic heart failure.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1997;11 Suppl 1():291-6.
-
1997: Asano K; Dutcher D L; Port J D; Minobe W A; Tremmel K D; Roden R L; Bohlmeyer T J; Bush E W; Jenkin M J; Abraham W T; Raynolds M V; Zisman L S; Perryman M B; Bristow M R
Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium.
Circulation 1997;95(5):1193-200.
-
1997: Cohn J N; Bristow M R; Chien K R; Colucci W S; Frazier O H; Leinwand L A; Lorell B H; Moss A J; Sonnenblick E H; Walsh R A; Mockrin S C; Reinlib L
Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research.
Circulation 1997;95(4):766-70.
-
1996: Gilbert E M; Abraham W T; Olsen S; Hattler B; White M; Mealy P; Larrabee P; Bristow M R
Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.
Circulation 1996;94(11):2817-25.
-
1996: Bristow M R; Gilbert E M; Abraham W T; Adams K F; Fowler M B; Hershberger R E; Kubo S H; Narahara K A; Ingersoll H; Krueger S; Young S; Shusterman N
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
Circulation 1996;94(11):2807-16.
-
1996: Colucci W S; Packer M; Bristow M R; Gilbert E M; Cohn J N; Fowler M B; Krueger S K; Hershberger R; Uretsky B F; Bowers J A; Sackner-Bernstein J D; Young S T; Holcslaw T L; Lukas M A
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
Circulation 1996;94(11):2800-6.
-
1996: Wagoner L E; Taylor D O; Olsen S L; Bristow M R; O'Connell J B; Hammond E H; Lappe D L; Renlund D G
Cyclophosphamide in cardiac transplant recipients with frequent rejection: a six-year retrospective review.
Clinical transplantation 1996;10(5):437-43.
-
1996: Taylor D O; Bristow M R; O'Connell J B; Price G D; Hammond E H; Doty D B; Karwande S V; Gay W A; Jones K W; Lappé D; Renlund D G
Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1996;15(10):1039-46.
-
1996: Quaife R A; Gilbert E M; Christian P E; Datz F L; Mealey P C; Volkman K; Olsen S L; Bristow M R
Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy.
The American journal of cardiology 1996;78(7):779-84.
-
1996: Ma H; Hammond E H; Taylor D O; Yowell R L; Bristow M R; O'Connell J B; Renlund D G
The repetitive histologic pattern of vascular cardiac allograft rejection. Increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3).
Transplantation 1996;62(2):205-10.
-
1996: Packer M; Bristow M R; Cohn J N; Colucci W S; Fowler M B; Gilbert E M; Shusterman N H
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
The New England journal of medicine 1996;334(21):1349-55.
-
1996: Yoshikawa T; Port J D; Asano K; Chidiak P; Bouvier M; Dutcher D; Roden R L; Minobe W; Tremmel K D; Bristow M R
Cardiac adrenergic receptor effects of carvedilol.
European heart journal 1996;17 Suppl B():8-16.
-
1996: Pende A; Tremmel K D; DeMaria C T; Blaxall B C; Minobe W A; Sherman J A; Bisognano J D; Bristow M R; Brewer G; Port J
Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway.
The Journal of biological chemistry 1996;271(14):8493-501.
-
1996: Focaccio A; Peeters G; Movsesian M; Roden R; Eki Y; Krall J; Bristow M R
Mechanism of action of OPC-8490 in human ventricular myocardium.
Circulation 1996;93(4):817-25.
-
1996: Renlund D G; Taylor D O; Ensley R D; O'Connell J B; Gilbert E M; Bristow M R; Ma H; Yanowitz F G
Exercise capacity after heart transplantation: influence of donor and recipient characteristics.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1996;15(1 Pt 1):16-24.
-
1995: White M; Yanowitz F; Gilbert E M; Larrabee P; O'Connell J B; Anderson J L; Renlund D; Mealey P; Abraham W T; Bristow M R
Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy.
The American journal of cardiology 1995;76(17):1271-6.
-
1995: Gilbert E M; Hershberger R E; Wiechmann R J; Movsesian M A; Bristow M R
Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart.
Chest 1995;108(6):1524-32.
-
1995: Bristow M R; Abraham W T
Anti-adrenergic effects of angiotensin converting enzyme inhibitors.
European heart journal 1995;16 Suppl K():37-41.
-
1995: Jaggers J; Fullerton D A; Campbell D N; Andrea B; Jones S D; Brown J M; Wolfel E E; Lindenfeld J; Grover F L; Bristow M R
Cardiac allograft failure: successful use of biventricular assist device.
The Annals of thoracic surgery 1995;60(5):1409-11.
-
1995: Bristow M R; Gilbert E M
Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure.
European heart journal 1995;16 Suppl F():20-31.
-
1995: Olsen S L; Gilbert E M; Renlund D G; Taylor D O; Yanowitz F D; Bristow M R
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Journal of the American College of Cardiology 1995;25(6):1225-31.
-
1995: Deisher T A; Ginsburg R; Fowler M B; Billingham M E; Bristow M R
Spontaneous reversibility of catecholamine-induced cardiotoxicity in rats.
The American journal of cardiovascular pathology 1995;5(1):79-88.
-
1995: Abraham W T; Raynolds M V; Gottschall B; Badesch D B; Wynne K M; Groves B M; Lowes B D; Bristow M R; Perryman M B; Voelkel N F
Importance of angiotensin-converting enzyme in pulmonary hypertension.
Cardiology 1995;86 Suppl 1():9-15.
-
1994: Abraham W T; Lowes B D; White M; Ferguson D A; Scheffel C A; Wolfel E E; Lindenfeld J; Bristow M R
Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure.
Journal of cardiac failure 1994;1(1):57-62.
-
1994: Taylor D O; Bristow M R; O'Connell J B; Ensley R D; Olsen S L; Hammond E H; Wagoner L E; Renlund D G
A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation. Decreased sensitization to OKT3.
Transplantation 1994;58(6):645-9.
-
1994: Bristow M R; O'Connell J B; Gilbert E M; French W J; Leatherman G; Kantrowitz N E; Orie J; Smucker M L; Marshall G; Kelly P
Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.
Circulation 1994;89(4):1632-42.
-
1994: Bristow M R; Lowes B D
Low-dose inotropic therapy for ambulatory heart failure.
Coronary artery disease 1994;5(2):112-8.
-
1994: Bristow M R
Use of oral enoximone in pharmacologic bridging to cardiac transplantation.
Zeitschrift für Kardiologie 1994;83 Suppl 2():15-9.
-
1993: Wagoner L E; Olsen S L; Bristow M R; O'Connell J B; Taylor D O; Lappe D L; Renlund D G
Cyclophosphamide as an alternative to azathioprine in cardiac transplant recipients with suspected azathioprine-induced hepatotoxicity.
Transplantation 1993;56(6):1415-8.
-
1993: Bristow M R; Minobe W A; Raynolds M V; Port J D; Rasmussen R; Ray P E; Feldman A M
Reduced beta 1 receptor messenger RNA abundance in the failing human heart.
The Journal of clinical investigation 1993;92(6):2737-45.
-
1993: Bristow M R
Changes in myocardial and vascular receptors in heart failure.
Journal of the American College of Cardiology 1993;22(4 Suppl A):61A-71A.
-
1993: Raynolds M V; Bristow M R; Bush E W; Abraham W T; Lowes B D; Zisman L S; Taft C S; Perryman M B
Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy.
Lancet 1993;342(8879):1073-5.
-
1993: Gilbert E M; Sandoval A; Larrabee P; Renlund D G; O'Connell J B; Bristow M R
Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart.
Circulation 1993;88(2):472-80.
-
1993: Feldman A M; Bristow M R; Parmley W W; Carson P E; Pepine C J; Gilbert E M; Strobeck J E; Hendrix G H; Powers E R; Bain R P
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
The New England journal of medicine 1993;329(3):149-55.
-
1993: Deisher T A; Narita H; Zera P; Ginsburg R; Bristow M R; Billingham M E; Fowler M B; Hoffman B B
Protective effect of clentiazem against epinephrine-induced cardiac injury in rats.
The Journal of pharmacology and experimental therapeutics 1993;266(1):262-9.
-
1993: Ensley R D; Bristow M R; Olsen S L; Taylor D O; Hammond E H; O'Connell J B; Dunn D; Osburn L; Jones K W; Kauffman R S
The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients.
Transplantation 1993;56(1):75-82.
-
1993: Olsen S L; Wagoner L E; Hammond E H; Taylor D O; Yowell R L; Ensley R D; Bristow M R; O'Connell J B; Renlund D G
Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1993;12(2):S135-42.
-
1993: Gilbert E M; Olsen S L; Renlund D G; Bristow M R
beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy.
The American journal of cardiology 1993;71(9):23C-29C.
-
1993: Bristow M R
Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents.
The American journal of cardiology 1993;71(9):12C-22C.
-
1992: Ratkovec R M; Hammond E H; O'Connell J B; Bristow M R; DeWitt C W; Richenbacher W E; Millar R C; Renlund D G
Outcome of cardiac transplant recipients with a positive donor-specific crossmatch--preliminary results with plasmapheresis.
Transplantation 1992;54(4):651-5.
-
1992: Port J D; Debellis C C; Klein J; Peeters G A; Barry W H; Bristow M R
Pharmacological characterization of chick and frog beta adrenergic receptors in primary cultures of myocardial cells.
The Journal of pharmacology and experimental therapeutics 1992;262(1):217-24.
-
1992: Hammond E H; Yowell R L; Price G D; Menlove R L; Olsen S L; O'Connell J B; Bristow M R; Doty D B; Millar R C; Karwande S V
Vascular rejection and its relationship to allograft coronary artery disease.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1992;11(3 Pt 2):S111-9.
-
1992: Merigan T C; Renlund D G; Keay S; Bristow M R; Starnes V; O'Connell J B; Resta S; Dunn D; Gamberg P; Ratkovec R M
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
The New England journal of medicine 1992;326(18):1182-6.
-
1992: Price G D; Olsen S L; Taylor D O; O'Connell J B; Bristow M R; Renlund D G
Corticosteroid-free maintenance immunosuppression after heart transplantation: feasibility and beneficial effects.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1992;11(2 Pt 2):403-14.
-
1992: Bristow M R; Minobe W; Rasmussen R; Larrabee P; Skerl L; Klein J W; Anderson F L; Murray J; Mestroni L; Karwande S V
Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms.
The Journal of clinical investigation 1992;89(3):803-15.
-
1992: Marks J D; Karwande S V; Richenbacher W E; Jones K W; Doty D B; Millar R C; O'Connell J B; Renlund D G; Bristow M R; Pantalos G M
Perioperative mechanical circulatory support for transplantation.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1992;11(1 Pt 1):117-28.
-
1992: Anderson F L; Port J D; Reid B B; Larrabee P; Hanson G; Bristow M R
Myocardial catecholamine and neuropeptide Y depletion in failing ventricles of patients with idiopathic dilated cardiomyopathy. Correlation with beta-adrenergic receptor downregulation.
Circulation 1992;85(1):46-53.
-
1992: Bristow M R; Larrabee P; Minobe W; Roden R; Skerl L; Klein J; Handwerger D; Port J D; Müller-Beckmann B
Receptor pharmacology of carvedilol in the human heart.
Journal of cardiovascular pharmacology 1992;19 Suppl 1():S68-80.
-
1992: Bristow M R; Larrabee P; Müller-Beckmann B; Minobe W; Roden R; Skerl L; Klein J; Handwerger D; Port J D
Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.
The Clinical investigator 1992;70 Suppl 1():S105-13.
-
1992: Bristow M R; Feldman A M
Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease.
Basic research in cardiology 1992;87 Suppl 1():15-35.
-
1992: Anderson F L; Port J D; Reid B B; Hanson G; Kralios A C; Hershberger R E; Bristow M R
Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy.
Journal of cardiovascular pharmacology 1992;20(5):800-6.
-
1991: Feldman A M; Ray P E; Bristow M R
Expression of alpha-subunits of G proteins in failing human heart: a reappraisal utilizing quantitative polymerase chain reaction.
Journal of molecular and cellular cardiology 1991;23(12):1355-8.
-
1991: Richenbacher W E; Karwande S V; Shaddy R E; Renlund D G; Bristow M R; O'Connell J B; Gay W A
Cardiac transplantation in a patient with a single ventricle and transposition of the great vessels.
The Annals of thoracic surgery 1991;52(4):871-3.
-
1991: Bristow M R; Anderson F L; Port J D; Skerl L; Hershberger R E; Larrabee P; O'Connell J B; Renlund D G; Volkman K; Murray J
Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy.
Circulation 1991;84(3):1024-39.
-
1991: Movsesian M A; Smith C J; Krall J; Bristow M R; Manganiello V C
Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.
The Journal of clinical investigation 1991;88(1):15-9.
-
1991: Feldman A M; Ray P E; Silan C M; Mercer J A; Minobe W; Bristow M R
Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction.
Circulation 1991;83(6):1866-72.
-
1991: O'Connell J B; Gilbert E M; Renlund D G; Bristow M R
Enoximone as a bridge to heart transplantation: the Utah experience.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1991;10(3):477-81.
-
1991: Hammond E H; Ensley R D; Yowell R L; Craven C M; Bristow M R; Renlund D G; O'Connell J B
Vascular rejection of human cardiac allografts and the role of humoral immunity in chronic allograft rejection.
Transplantation proceedings 1991;23(2 Suppl 2):26-30.
-
1991: Feldman A M; Jackson D G; Bristow M R; Cates A E; Van Dop C
Immunodetectable levels of the inhibitory guanine nucleotide-binding regulatory proteins in failing human heart: discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate.
Journal of molecular and cellular cardiology 1991;23(4):439-52.
-
1991: Hershberger R E; Feldman A M; Bristow M R
A1-adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium.
Circulation 1991;83(4):1343-51.
-
1991: Hershberger R E; Feldman A M; Anderson F L; Kimball J A; Wynn J R; Bristow M R
Mr 40,000 and Mr 39,000 pertussis toxin substrates are increased in surgically denervated dog ventricular myocardium.
Journal of cardiovascular pharmacology 1991;17(4):568-75.
-
1991: O'Connell J B; Renlund D G; Hammond E H; Wittwer C T; Yowell R L; DeWitt C W; Jones K W; Gay W A; Menlove R L; Bristow M R
Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1991;10(2):217-21; discussion 221-2.
-
1991: O'Connell J B; Renlund D G; Bristow M R; Hammond E H
Detection of allograft endothelial cells of recipient origin following ABO-compatible, nonidentical cardiac transplantation.
Transplantation 1991;51(2):438-42.
-
1991: Ensley R D; Hammond E H; Renlund D G; Yowell R L; Bristow M R; DeWitt C W; Menlove R L; Ratkovec R M; O'Connell J B
Clinical manifestations of vascular rejection in cardiac transplantation.
Transplantation proceedings 1991;23(1 Pt 2):1130-2.
-
1991: O'Connell J B; Bristow M R; Hammond E H; Menlove R L; Ensley R D; Ratkovec R M; Renlund D G
Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection.
Transplantation proceedings 1991;23(1 Pt 2):1157-9.
-
1991: Moore C K; O'Connell J B; Renlund D G; Bristow M R; Hammond E H
Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization.
Transplantation proceedings 1991;23(1 Pt 2):1055-8.
-
1991: Gilbert E M; O'Connell J B; Bristow M R
Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade.
Heart and vessels. Supplement 1991;6():29-39.
-
1990: Olsen S L; O'Connell J B; Bristow M R; Renlund D G
Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection.
Transplantation 1990;50(5):773-5.
-
1990: Hammond E H; Wittwer C T; Greenwood J; Knape W A; Yowell R L; Menlove R L; Craven C; Renlund D G; Bristow M R; DeWitt C W
Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis.
Transplantation 1990;50(5):776-82.
-
1990: O'Connell J B; Bristow M R; Rasmussen L G; Ratkovec R M; Gay W A; Jones K W; Renlund D G
Cardiac allograft function with corticosteroid-free maintenance immunosuppression.
Circulation 1990;82(5 Suppl):IV318-21.
-
1990: Bristow M R
The surgically denervated, transplanted human heart.
Circulation 1990;82(2):658-60.
-
1990: Bristow M R; Hershberger R E; Port J D; Gilbert E M; Sandoval A; Rasmussen R; Cates A E; Feldman A M
Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium.
Circulation 1990;82(2 Suppl):I12-25.
-
1990: Ratkovec R M; Wray R B; Renlund D G; O'Connell J B; Bristow M R; Gay W A; Karwande S V; Doty D B; Millar R C; Menlove R L
Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease after cardiac transplantation.
The Journal of thoracic and cardiovascular surgery 1990;100(1):6-12.
-
1990: Moore C K; Bristow M R; Renlund D G; Rasmussen L G; O'Connell J B
Long-term morbidity of cyclosporine with corticosteroid-free maintenance immunosuppression in cardiac transplantation.
Transplantation proceedings 1990;22(3 Suppl 1):25-9.
-
1990: Hershberger R E; Wynn J R; Sundberg L; Bristow M R
Mechanism of action of bucindolol in human ventricular myocardium.
Journal of cardiovascular pharmacology 1990;15(6):959-67.
-
1990: Hammond E H; Watson F S; Bristow M R; O'Connell J B; Gilbert E M; Doty D B; Renlund D G
Fibrinoid necrosis of a temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD3 antibody (OKT3).
The Journal of heart transplantation 1990;9(3 Pt 1):236-8.
-
1990: Renlund D G; O'Connell J B; Bristow M R
Strategies of immunosuppression in cardiac transplantation.
Seminars in thoracic and cardiovascular surgery 1990;2(2):181-8.
-
1990: Gilbert E M; Anderson J L; Deitchman D; Yanowitz F G; O'Connell J B; Renlund D G; Bartholomew M; Mealey P C; Larrabee P; Bristow M R
Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo.
The American journal of medicine 1990;88(3):223-9.
-
1990: Port J D; Gilbert E M; Larrabee P; Mealey P; Volkman K; Ginsburg R; Hershberger R E; Murray J; Bristow M R
Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart.
Circulation 1990;81(3):929-38.
-
1990: Rasmussen R P; Minobe W; Bristow M R
Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium.
Biochemical pharmacology 1990;39(4):691-6.
-
1990: Feldman A M; Bristow M R
The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy.
Cardiology 1990;77 Suppl 1():1-32.
-
1989: Hammond E H; Yowell R L; Nunoda S; Menlove R L; Renlund D G; Bristow M R; Gay W A; Jones K W; O'Connell J B
Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications.
The Journal of heart transplantation 1989;8(6):430-43.
-
1989: Movsesian M A; Bristow M R; Krall J
Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy.
Circulation research 1989;65(4):1141-4.
-
1989: Wittwer C T; Knape W A; Bristow M R; Gilbert E M; Renlund D G; O'Connell J B; DeWitt C W
The quantitative flow cytometric plasma OKT3 assay. Its potential application in cardiac transplantation.
Transplantation 1989;48(3):533-5.
-
1989: Hershberger R E; Anderson F L; Bristow M R
Vasoactive intestinal peptide receptor in failing human ventricular myocardium exhibits increased affinity and decreased density.
Circulation research 1989;65(2):283-94.
-
1989: Hegewald M G; O'Connell J B; Renlund D G; Lee H R; Burton N A; Karwande S V; Jones K W; Lassetter J E; Bristow M R
OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
The Journal of heart transplantation 1989;8(4):303-9; discussion 309-10.
-
1989: Bristow M R; Port J D; Hershberger R E; Gilbert E M; Feldman A M
The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure.
European heart journal 1989;10 Suppl B():45-54.
-
1989: Brodde O E; Michel M C; Gordon E P; Sandoval A; Gilbert E M; Bristow M R
Beta-adrenoceptor regulation in the human heart: can it be monitored in circulating lymphocytes?
European heart journal 1989;10 Suppl B():2-10.
-
1989: Renlund D G; Bristow M R; Crandall B G; Burton N A; Doty D B; Karwande S V; Gay W A; Jones K W; Hegewald M G; Hagan M E
Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression.
The Journal of heart transplantation 1989;8(3):214-9; discussion 219-20.
-
1989: O'Connell J B; Renlund D G; Gay W A; DeWitt C W; Hammond E H; Yowell R L; Jones K W; Karwande S V; Doty D B; Bristow M R
Efficacy of OKT3 retreatment for refractory cardiac allograft rejection.
Transplantation 1989;47(5):788-92.
-
1989: Feldman A M; Cates A E; Bristow M R; Van Dop C
Altered expression of alpha-subunits of G proteins in failing human hearts.
Journal of molecular and cellular cardiology 1989;21(4):359-65.
-
1989: Bristow M R; Hershberger R E; Port J D; Minobe W; Rasmussen R
Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.
Molecular pharmacology 1989;35(3):295-303.
-
1989: Heilbrunn S M; Shah P; Bristow M R; Valantine H A; Ginsburg R; Fowler M B
Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.
Circulation 1989;79(3):483-90.
-
1989: Gilbert E M; Eiswirth C C; Mealey P C; Larrabee P; Herrick C M; Bristow M R
Beta-adrenergic supersensitivity of the transplanted human heart is presynaptic in origin.
Circulation 1989;79(2):344-9.
-
1988: Bristow M R; Minobe W; Rasmussen R; Hershberger R E; Hoffman B B
Alpha-1 adrenergic receptors in the nonfailing and failing human heart.
The Journal of pharmacology and experimental therapeutics 1988;247(3):1039-45.
-
1988: Gay W A; O'Connell J G; Burton N A; Karwande S V; Renlund D G; Bristow M R
OKT3 monoclonal antibody in cardiac transplantation. Experience with 102 patients.
Annals of surgery 1988;208(3):287-90.
-
1988: Anderson F L; Kralios A C; Hershberger R; Bristow M R
Desensitization of myocardial but not coronary VIP receptor-mediated responses in dogs.
The American journal of physiology 1988;255(3 Pt 2):H601-7.
-
1988: Anderson F L; Kralios A C; Hershberger R; Bristow M R
Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: comparison with isoproterenol and forskolin.
Journal of cardiovascular pharmacology 1988;12(3):365-71.
-
1988: Feldman A M; Cates A E; Veazey W B; Hershberger R E; Bristow M R; Baughman K L; Baumgartner W A; Van Dop C
Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart.
The Journal of clinical investigation 1988;82(1):189-97.
-
1988: Bristow M R; Sandoval A B; Gilbert E M; Deisher T; Minobe W; Rasmussen R
Myocardial alpha- and beta-adrenergic receptors in heart failure: is cardiac-derived norepinephrine the regulatory signal?
European heart journal 1988;9 Suppl H():35-40.
-
1988: Yowell R L; Hammond E H; Bristow M R; Watson F S; Renlund D G; O'Connell J B
Acute vascular rejection involving the major coronary arteries of a cardiac allograft.
The Journal of heart transplantation 1988;7(3):191-7.
-
1988: Wittwer C T; Bristow M R; Gilbert E M; Renlund D G; O'Connell J B; DeWitt C W
OKT3 therapy as a cause of high panel-reactive antibodies in serum using standard microcytotoxicity techniques.
Transplantation 1988;45(4):832-4.
-
1988: Watson F S; O'Connell J B; Amber I J; Renlund D G; Classen D; Johnston J M; Smith C B; Bristow M R
Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG).
The Journal of heart transplantation 1988;7(2):102-5.
-
1988: Bristow M R; Gilbert E M; O'Connell J B; Renlund D G; Watson F S; Hammond E; Lee R G; Menlove R
OKT3 monoclonal antibody in heart transplantation.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1988;11(2):135-40.
-
1988: Bristow M R
The beta-adrenergic receptor. Configuration, regulation, mechanism of action.
Postgraduate medicine 1988;Spec No():19-26.
-
1987: Gilbert E M; Renlund D G; O'Connell J B; Eiswirth C C; Rothstein G; Gay W A; Bristow M R
Immunosuppressive efficacy of vincristine in heart transplantation: a preliminary report.
The Journal of heart transplantation 1987;6(6):369-74.
-
1987: Gilbert E M; Eiswirth C C; Renlund D G; Menlove R L; DeWitt C W; Freedman L A; Herrick C M; Gay W A; Bristow M R
Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection.
Transplantation proceedings 1987;19(2 Suppl 1):45-53.
-
1987: Gilbert E M; Dewitt C W; Eiswirth C C; Renlund D G; Menlove R L; Freedman L A; Herrick C M; Gay W A; Bristow M R
Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody.
The American journal of medicine 1987;82(2):202-6.
-
1987: Bristow M R; Ginsburg R; Gilbert E M; Hershberger R E
Heterogeneous regulatory changes in cell surface membrane receptors coupled to a positive inotropic response in the failing human heart.
Basic research in cardiology 1987;82 Suppl 2():369-76.
-
1986: Bristow M R; Ginsburg R; Umans V; Fowler M; Minobe W; Rasmussen R; Zera P; Menlove R; Shah P; Jamieson S
Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.
Circulation research 1986;59(3):297-309.
Sign-in to see more
